{"protocolSection": {"identificationModule": {"nctId": "NCT00496834", "nctIdAliases": ["NCT01001416"], "orgStudyIdInfo": {"id": "0954-330"}, "secondaryIdInfos": [{"id": "2007_015"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)", "officialTitle": "A Randomized, Open-label, Comparative, Non-inferiority, Multicenter Study to Compare Efficacy of Losartan Potassium Group and Carvedilol Group on Arterial Stiffness in Essential Hypertension Patients"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-09-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-07-03", "studyFirstSubmitQcDate": "2007-07-03", "studyFirstPostDateStruct": {"date": "2007-07-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-08-26", "resultsFirstSubmitQcDate": "2010-11-18", "resultsFirstPostDateStruct": {"date": "2010-12-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the essential hypertension."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 201, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Losartan or Losartan/HCTZ", "interventionNames": ["Drug: losartan potassium", "Drug: Comparator: losartan (+) hydrochlorothiazide (HCTZ)"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "Carvedilol or Carvedilol/HCTZ", "interventionNames": ["Drug: Comparator: carvedilol", "Drug: Comparator: carvedilol (+) hydrochlorothiazide"]}], "interventions": [{"type": "DRUG", "name": "losartan potassium", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Comparator: carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or Dilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "Comparator: losartan (+) hydrochlorothiazide (HCTZ)", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Comparator: carvedilol (+) hydrochlorothiazide", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or Dilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "description": "Analysis was performed in the modified intention to treat (mITT) population.", "timeFrame": "Baseline and 24 Weeks"}, {"measure": "PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "description": "Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.", "timeFrame": "Baseline and 24 Weeks"}], "secondaryOutcomes": [{"measure": "Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "timeFrame": "Baseline and 24 weeks"}, {"measure": "Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "timeFrame": "Baseline and 24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or Female adults, 18 years or over\n* Essential Hypertension with mean SBP (systolic blood pressure) \u2265 140 mm Hg or mean DBP (diastolic blood pressure) \u2265 90 mm Hg\\* when blood pressure is measured at Visit 1(week -2) and at Visit 2(week 0).\n\nIf diabetes patients, mean SBP \u2265 130 mm Hg or mean DBP \u2265 80 mm Hg (Mean of blood pressure values measured consecutively at least 2 minutes apart)\n\n* Patient who is willing to, and is able to sign the informed consent form\n\nExclusion Criteria:\n\n* Patient Is Pregnant Or Breastfeeding, Or Expecting To Conceive Within The Projected Duration Of The Study\n* Patient Has Known Or Suspected Secondary Hypertension Of Any Etiology\n* Patient has history of malignant hypertension\n* Patient has history of cerebrovascular accident (cerebral infarction) or myocardiac infarction within the last 6 months\n* Patient takes antihypertensive drugs", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "7 centers participated in this study (7 medical centers of university).\n\nFPE (First patient enrolled): Feb-2008, FPI (First patient in): Feb-2008, LPO (Last patient out): Sep-2009", "groups": [{"id": "FG000", "title": "Losartan", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)."}, {"id": "FG001", "title": "Carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or\n\nDilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "101"}, {"groupId": "FG001", "numSubjects": "100"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "83"}, {"groupId": "FG001", "numSubjects": "87"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Contraindicated medication administered", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Inclusion/exclusion criteria not met", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "IP administration violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Blood Pressure control failure", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Losartan", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)."}, {"id": "BG001", "title": "Carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or\n\nDilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "101"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "201"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.0", "spread": "9.3"}, {"groupId": "BG001", "value": "50.1", "spread": "10.2"}, {"groupId": "BG002", "value": "49.6", "spread": "9.7"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": ">= 18 to < 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "91"}, {"groupId": "BG002", "value": "187"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "63"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "120"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "81"}]}]}]}, {"title": "DBP (diastolic blood pressure)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "96.4", "spread": "8.8"}, {"groupId": "BG001", "value": "96.4", "spread": "8.3"}, {"groupId": "BG002", "value": "96.4", "spread": "8.5"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Centimeters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "164.9", "spread": "7.8"}, {"groupId": "BG001", "value": "163.3", "spread": "9.2"}, {"groupId": "BG002", "value": "164.1", "spread": "8.5"}]}]}]}, {"title": "PWV (pulse wave velocity)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "meters/second", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.6", "spread": "1.4"}, {"groupId": "BG001", "value": "7.7", "spread": "1.4"}, {"groupId": "BG002", "value": "7.6", "spread": "1.4"}]}]}]}, {"title": "Pulse", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "BPM (beats per minute)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71.8", "spread": "10.0"}, {"groupId": "BG001", "value": "72.3", "spread": "10.0"}, {"groupId": "BG002", "value": "72.0", "spread": "10.0"}]}]}]}, {"title": "SBP (systolic blood pressure)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "150.6", "spread": "11.0"}, {"groupId": "BG001", "value": "152.7", "spread": "12.1"}, {"groupId": "BG002", "value": "151.6", "spread": "11.6"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.9", "spread": "10.6"}, {"groupId": "BG001", "value": "69.9", "spread": "13.2"}, {"groupId": "BG002", "value": "70.4", "spread": "12.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "description": "Analysis was performed in the modified intention to treat (mITT) population.", "populationDescription": "Participants for analysis was modified intention to treat (Number of patients: Losartan group was 88, Carvedilol group was 94). Missing data were imputed by the last observation carried forward (LOCF) technique.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters/second", "timeFrame": "Baseline and 24 Weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration and 4) did not commit major violation."}, {"id": "OG001", "title": "Carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or\n\nDilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration and 4) did not commit major violation."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.28", "spread": "1.29"}, {"groupId": "OG001", "value": "-0.12", "spread": "1.55"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Participants for analysis was modified intention to treat (Number of patients: Losartan group was 88, Carvedilol group was 94).", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE_LEGACY", "nonInferiorityComment": "non-inferiority margin= -1.5m/s", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.83", "ciUpperLimit": "0.01", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.43", "estimateComment": "The lower limit of \u2265-1.5m/s was judged to prove the non-inferiority of the test group to the control group."}]}, {"type": "PRIMARY", "title": "PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "description": "Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.", "populationDescription": "Participants for analysis was per protocol (Number of patients: Losartan group was 54, Carvedilol group was 67). Missing data were imputed by the last observation carried forward (LOCF) technique. For the primary efficacy endpoints, Per protocol analysis approach was supplementary used.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters/second", "timeFrame": "Baseline and 24 Weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration 4) did not commit major violation and 5) did not have protocol violation including erroneous prescription of the investigational drug, baseline PWV test date violation, PWV test date violation 24 weeks after the administration of the investigational drug, titration violation, use of prohibited concomitant drugs, visit window violation and inclusion/exclusion criteria violation."}, {"id": "OG001", "title": "Carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or\n\nDilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration 4) did not commit major violation and 5) did not have protocol violation including erroneous prescription of the investigational drug, baseline PWV test date violation, PWV test date violation 24 weeks after the administration of the investigational drug, titration violation, use of prohibited concomitant drugs, visit window violation and inclusion/exclusion criteria violation."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "1.25"}, {"groupId": "OG001", "value": "-0.20", "spread": "1.50"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Participants for analysis was per protocol (Number of patients: Losartan group was 54, Carvedilol group was 67). For the primary efficacy endpoints, Per protocol analysis approach was supplementary used.", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE_LEGACY", "nonInferiorityComment": "non-inferiority margin=-1.5m/s", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.86", "ciUpperLimit": "0.15", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.40", "estimateComment": "The lower limit of \u2265-1.5m/s was judged to prove the non-inferiority of the test group to the control group."}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure (SBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "populationDescription": "Participants for analysis was modified intention to treat (Number of patients: Losartan group was 88, Carvedilol group was 94) Missing data were imputed by the last observation carried forward (LOCF) technique.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration and 4) did not commit major violation."}, {"id": "OG001", "title": "Carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or\n\nDilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration and 4) did not commit major violation."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.08", "spread": "14.59"}, {"groupId": "OG001", "value": "-14.81", "spread": "15.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.9032", "pValueComment": "Significance level=0.05", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "The secondary efficacy analysis was performed in the modified intention to treat population using t-test.", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Diastolic Blood Pressure (DBP) Mean Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug", "populationDescription": "Participants for analysis was modified intention to treat (Number of patients: Losartan group was 88, Carvedilol group was 94) Missing data were imputed by the last observation carried forward (LOCF) technique.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Losartan", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration and 4) did not commit major violation."}, {"id": "OG001", "title": "Carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or\n\nDilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who 1) had baseline measurements before randomization, 2) had taken the study drug more than once after randomization, 3) had one measurement after the initiation of the administration and 4) did not commit major violation."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.43", "spread": "9.29"}, {"groupId": "OG001", "value": "-7.81", "spread": "9.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.6574", "pValueComment": "Significance level=0.05", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "The secondary efficacy analysis was performed in the modified intention to treat population using t-test", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were recorded from first administration of study drug up to 14 days after the administration of final dose.", "eventGroups": [{"id": "EG000", "title": "Losartan", "description": "Once daily , Cozaar\u00ae (losartan) 50 mg, Cozaar\u00ae (losartan) 100 mg, Cozaar Plus\u00ae-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus\u00ae-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Subjects who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who received the investigational drug at least more than once.", "seriousNumAffected": 5, "seriousNumAtRisk": 101, "otherNumAffected": 35, "otherNumAtRisk": 101}, {"id": "EG001", "title": "Carvedilol", "description": "Once daily, Dilatrend Tab\u00ae (carvedilol) 12.5 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg, Dilatrend Tab\u00ae (carvedilol) 25 mg plus half Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg) or\n\nDilatrend Tab\u00ae (carvedilol) 25 mg plus full Dichlozid Tab\u00ae (hydrochlorothiazide 25 mg), 24 weeks (Subjects who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who received the investigational drug at least more than once.", "seriousNumAffected": 6, "seriousNumAtRisk": 100, "otherNumAffected": 51, "otherNumAtRisk": 100}], "seriousEvents": [{"term": "Myelitis transverse", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Mouth haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 100}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Prinzmetal angina", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 12, "numAffected": 9, "numAtRisk": 100}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Dizziness postural", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Duodenal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Mouth ulceration", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Periodontitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Reflux gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Reflux oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 100}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Bronchiolitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Pharyngotonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Face oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Joint sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Musculoskeletal stiffness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Myofascial pain syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Erectile dysfunction", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Menopausal symptoms", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Pollakiuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Atrioventricular block first degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Anorexia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Pruritus allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Rash maculo-papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Eye pain", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Benign colonic neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}]}, {"term": "Tinnitus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Tooth extraction", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 101}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26", "removedCountries": ["Korea, Republic of"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M26188", "name": "Atherosclerosis", "relevance": "LOW"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Depressive Disorder", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Prevent", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Rich", "relevance": "HIGH"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}